Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in Adult ADHD With or Without Mood Disorders
NCT05832489Phase 3Recruiting
- Sponsor
- Strasbourg University Hospital
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Effect of methylphenidate on the task vs. rest activation differential at 2 hours. Started Feb 2024; status: recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05832489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832489.